Bio-nanoparticle based therapeutic vaccine induces immunogenic response against triple negative breast cancer.
Triple negative breast cancer (TNBC) is more aggressive and has a poorer prognosis than other sub-types of breast tumors. This study elucidates how aspartate beta-hydroxylase (ASPH) network promotes drug resistance, and immunotherapy targeting ASPH may improve the efficacy of Doxorubicin (DOX) therapy. An orthotopic model of breast cancer generated by 4T1 cells in immunocompetent mice was used to explore efficacy of immunotherapy in combination with DOX chemotherapy. We evaluated mRNA and protein expression in cultured tumor cells and tissue, as well as assessed cell proliferation, apoptosis, soluble factors/cytokine production, immune cell population diversity and function. We observed that ASPH expression enables TNBC cells to exhibit primary resistance to DOX induced single-/double-strand breaks (SSB/DSB) and enhanced proliferation and survival. Specific bio-nanoparticle based therapeutic vaccine (BNP-TV) promoted ASPH uptake by and maturation of DCs. This BNP-TV combined with DOX induces immunogenic cell death (ICD) in orthotopic xenograft tumors and significantly suppressed primary mammary tumor growth and distant multi-organ metastases. Immunogenic cell death induced by BNP-TV targeting ASPH combined with DOX provides opportunities to treat a highly resistant and metastatic form of breast cancer.
['Bai|Xuewei|X|', 'Zhou|Yanmei|Y|', 'Lin|Qiushi|Q|', 'Huang|Chiung-Kuei|CK|', 'Zhang|Songhua|S|', 'Carlson|Rolf I|RI|', 'Ghanbari|Hossein|H|', 'Sun|Bei|B|', 'Wands|Jack R|JR|', 'Dong|Xiaoqun|X|']
doxorubicin immunogenic cell death Aspartate β-hydroxylase metastasis λ-phage